Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical

Status Active, not recruiting

Clinical Trial Summary

Methanol poisoning could result in severe optic neuropathy, profound visual loss and finally optic atrophy and permanent, irreversible optic atrophy and visual loss. Erythropoietin (EPO) has recently emerged as a drug that may help retinal ganglion cell loss and improve optic nerve function in some acquired types of optic neuropathy including traumatic optic neuropathy ,ischemic optic neuropathy and optic neuritis .It has been found that EPO offer some protection to the optic nerve and retina when they are injured and apoptosis process starts in retinal ganglion cells. The standard treatments of methanol poisoning are reanimation, metabolic stabilization, and inhibition of alcohol dehydrogenase by antagonist agents and elimination of toxic metabolites in early phase of toxicity by dialysis. However, after established optic neuropathy and visual loss there is little chance, if any, for visual recovery and no definitive treatment exist for treatment in these cases. The investigators recently reported the investigators preliminary results on 16 cases with methanol poisoning and found a beneficial effect of systemic erythropoietin in methanol associated optic neuropathy. Now, the investigators aim to investigate the effect of this agent in a clinical trial.

The purpose of this study is to determine if EPO could improves optic nerve function and help patients to improve visual recovery after methanol poisoning. Primary outcome measure would be best-corrected visual function and secondary outcome measure is ocular coherence tomography (OCT) measure of mean peripapillary nerve fiber layer thickness. Results of this study could be very valuable in formulating an evidence-based management of Methanol Associated Optic Neuropathy(MAON) and provide a high level evidence for changing the practice on management of methanol poisoning . Also it could provide valuable data for neuroprotective effects of erythropoietin specifically in neuroscience and ophthalmology.

The EPO-MAON trial is designed as a randomized, controlled, observer, and interpreter blinded mono-center pilot trial with two parallel groups and a primary endpoint of best corrected visual acuity during 120 days after enrollment into treatment groups.

All patients with methanol poisoning referred to Farabi hospital will be examined and evaluated for best-corrected visual acuity, pupillary light reflexes, relative afferent pupillary defect, color vision (Ishihara plates), fundus photography, slit lamp exam of anterior segment and fundus exam with 78 D lens.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02376881
Study type	Interventional
Source	Tehran University of Medical Sciences
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	March 2015
Completion date	March 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05130385` - High Resolution Optical Coherence Tomography
Terminated	`NCT01422525` - Changes of the Peripapillary Retinal Nerve Fiber Layer After Filtration Surgery in Glaucoma Patients	N/A
Terminated	`NCT00359632` - Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater	Phase 3
Completed	`NCT01270126` - Trial of Alternating Current Stimulation in Optic Neuropathy	N/A
Not yet recruiting	`NCT04289909` - Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)	N/A
Completed	`NCT04125043` - Accuracy of the Red Reflex Test in the Pediatric Population
Completed	`NCT02582164` - Long-Working Distance OCT for Children	N/A
Recruiting	`NCT06139523` - Optimize Pediatric OCT Imaging
Completed	`NCT01404247` - Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates	Phase 1
Recruiting	`NCT05626426` - Electrical Stimulation for the Treatment of Optic Neuropathies	N/A
Completed	`NCT04891211` - Retinal Changes in Vitamin D Deficiency	N/A
Completed	`NCT01280877` - Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT_optnerve)	N/A
Recruiting	`NCT04634383` - A Phase I Feasibility Study of an Intracortical Visual Prosthesis (ICVP) for People With Blindness	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms